Biophytis S.A. (6XB.F)

0,0022 0,0000 (0,00%) Ab 09:15AM CEST. Markt geöffnet.

Biophytis S.A.

Sorbonne University
BC 9, BAtiment A 4Eme Etage 4 place Jussieu Cedex 05
Paris 75005
France
33 1 44 27 23 00
https://www.biophytis.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 22

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Stanislas Veillet Ph.D.	Chairman of the Board & CEO	349k	N/A	1965
Mr. Nicolas Fellmann	Chief Financial Officer	N/A	N/A	1968
Mr. Waly Dioh Ph.D.	Chief Clinical Operating Officer	N/A	N/A	1969
Dr. Pierre J. Dilda Ph.D.	Chief Scientific Officer	N/A	N/A	1970
Dr. Rene Lafont	Scientific Advisor & Member of Scientific Advisory Board	N/A	N/A	1946
Dr. Rob van Maanen FFPM, M.B.A., M.D.	Chief Medical Officer	N/A	N/A	1971
Mr. Edouard Bieth	Chief Business Officer	N/A	N/A	1980
Ms. Chiara Baccelli	Chief Pharmaceutical Operations Officer & Quality Assurance Director	N/A	N/A	N/A
Ms. _ Teylan	Financial Controller	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

Corporate Governance

Biophytis S.A.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.